Association between anlotinib trough plasma concentration and treatment outcomes in advanced non-small-cell lung cancer

Ling Chen, Hong Jiang, Jun-jie Rao, Liusheng Wang, Wei Yan, Jian Ye, Jiang LouFrontiers in Oncology 2023 · DOI

Abstract

Considering these results, we propose that maintaining ANL C<sub>trough</sub> ≥ 10.29ng/ml was important for achieving the response in advanced NSCLC patients treated with ANL.

Introduction

Anlotinib (ANL) is a multi-targeted receptor tyrosine kinase inhibitor (TKI) used as a third-line or later treatment for advanced non-small-cell lung cancer (NSCLC). Despite standard dosing, patients exhibit significant variability in drug exposure, leading to unpredictable clinical outcomes. This study explores the relationship between ANL trough plasma concentration ($C_{trough}$) and clinical efficacy to determine if therapeutic drug monitoring (TDM) can optimize treatment and maximize patient outcomes.

Methods

A prospective study was conducted with 52 Chinese patients with advanced NSCLC receiving ANL monotherapy. Blood samples were collected on day 43 to measure $C_{trough}$ using a novel ultra-high-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method with zanubrutinib as an internal standard. Clinical response was evaluated via RECIST 1.1 criteria. Receiver Operating Characteristic (ROC) curves and the Youden index were utilized to identify the optimal $C_{trough}$ threshold for clinical response.

Results

The study confirmed high inter-patient variability in ANL exposure, with a coefficient of variation of 37.66%. The median $C_{trough}$ was 11.45 ng/ml, ranging from 3.69 to 26.36 ng/ml.

Distribution of anlotinib trough plasma concentration among the study cohort (n=52).

Statistical analysis revealed a clear exposure-response relationship. Patients achieving a Partial Response (PR) had a significantly higher median $C_{trough}$ (15.51 ng/ml) than those with Progressive Disease (PD) (7.44 ng/ml).

Comparison of anlotinib trough plasma concentrations across different clinical response categories: Partial Response (PR), Stable Disease (SD), and Progressive Disease (PD).

ROC analysis identified 10.29 ng/ml as the optimal threshold for predicting clinical response (AUC = 0.76). Patients with $C_{trough} \ge 10.29$ ng/ml achieved a disease control rate (DCR) of 96.67%, compared to 68.18% in the low-exposure group. While higher exposure increased the incidence of hand-foot syndrome (70.0% vs 36.36%) and TSH elevation, it did not significantly increase severe (Grade $\ge$ 3) toxicities.

Conclusion

Maintaining an ANL $C_{trough}$ of at least 10.29 ng/ml is critical for maximizing clinical response in advanced NSCLC. These findings support the implementation of TDM to personalize anlotinib dosing. Future multi-center studies are recommended to correlate these concentration thresholds with long-term survival outcomes like Progression-Free Survival (PFS) and Overall Survival (OS).

Summary updated

Abstract

Considering these results, we propose that maintaining ANL C<sub>trough</sub> ≥ 10.29ng/ml was important for achieving the response in advanced NSCLC patients treated with ANL.
BibTeX
@inproceedings{chen2023association,
  author = {Ling Chen and Hong Jiang and Jun-jie Rao and Liusheng Wang and Wei Yan and Jian Ye and Jiang Lou},
  title = {{Association between anlotinib trough plasma concentration and treatment outcomes in advanced non-small-cell lung cancer}},
  booktitle = {Frontiers in Oncology},
  year = {2023},
  doi = {10.3389/fonc.2023.1146362},
}
Figure